Major Depressive Disorder Pipeline Summary

DelveInsight’s, “Major Depressive Disorder - Pipeline Insight, 2026” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Major Depressive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Major Depressive Disorder: Understanding Major Depressive Disorder: Overview Major Depressive Disorder (MDD), also referred as depression, is a serious medical illness that disrupts a person’s mood, behavior, thought processes, apart from degrading the physical health. It should not be mistaken for the passing feelings of unhappiness that everyone experiences, nor should it be confused with the intense grief brought about by the death of a loved one. Sadness and grief are normal reactions to life stresses. MDD is one form of depressive illness, or mood disorder. Other forms include bipolar disorder (manic-depressive illness) and dysthymia. Depression can be difficult to detect due to subtle differences from normal sensations. Symptoms in children may include guilt, emptiness, self-dislike, and suicidal tendencies. Various symptoms experience by children includes guilt, feeling of emptiness, self-dislike, sense of failure, self-denigration, quality of mood, fears and Phobias, suicidal attempts etc. Research and psychiatric observation have identified specific signs of major depressive disorder. These include loss of interest in pleasurable activities, changes in appetite and weight, sleep disturbances, feelings of guilt or worthlessness, and a sense of hopelessness. Major Depressive Disorder (MDD) involves dysregulation of neurotransmitters like serotonin, norepinephrine, and dopamine, affecting mood regulation. Structural brain changes, particularly in areas like the hippocampus and prefrontal cortex, contribute to cognitive symptoms. Genetic predisposition, environmental stressors, and psychological factors also play significant roles in its onset and progression. Clinical suspicion is key to the diagnosis of MDD. Patients should be asked about depressed mood and/or lack of interest or pleasure when they present with nonspecific symptoms suggestive of depression. Clinicians should evaluate the patient for the following features: onset, duration, accompanying psychological symptoms, possible psychosocial precipitating factors (e.g., relationship problems, work-related stressors, or living conditions), and the effect of these symptoms on the patient’s daily life and function. Detailed history of past depressive or manic episodes, other psychiatric disorders, and possible use of alcohol or other substances should be obtained because these can significantly influence diagnosis and treatment decisions. Depression is among the most treatable of mental disorders. Between 80% and 90% percent of people with depression eventually respond well to treatment. Almost all patients gain some relief from their symptoms. Brain chemistry may contribute to an individual’s depression and may factor into their treatment. For this reason, antidepressants might be prescribed to help modify one’s brain chemistry. Antidepressants may produce some improvement within the first week or two of use yet full benefits may not be seen for two to three months. Serotonin-norepinephrine reuptake inhibitors (SNRIs) are also effective in treating depression and anxiety. "Major Depressive Disorder- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Major Depressive Disorder pipeline landscape is provided which includes the disease overview and Major Depressive Disorder treatment guidelines. The assessment part of the report embraces, in depth Major Depressive Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Major Depressive Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Report Highlights • The companies and academics are working to assess challenges and seek opportunities that could influence Major Depressive Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Major Depressive Disorder. Major Depressive Disorder Emerging Drugs Chapters This segment of the Major Depressive Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Major Depressive Disorder Emerging Drugs • HLP003: Helus Pharma HLP003 (formerly CYB003) is an orally administered, deuterated psilocin analog designed to offer the therapeutic benefits of psychedelics with improved pharmacokinetics, including greater stability and shorter duration of action. In Phase II studies, the drug has demonstrated rapid and durable antidepressant effects, with up to 75% remission at four months and sustained benefits after two doses. The drug has received FDA Breakthrough Therapy Designation, recognizing its potential to address unmet needs in depression treatment. Currently, the drug is in Phase III stage of its development for the treatment of Major depressive disorder. • Seltorexant: Janssen Research & Development Seltorexant is an investigational, orally administered selective orexin-2 receptor (OX2R) antagonist which targets the orexin system, which regulates wakefulness, arousal, and stress responses, offering a mechanism distinct from conventional monoaminergic antidepressants. Its mechanism of action (MOA) involves selectively blocking the OX2R, thereby reducing excessive neuronal arousal and stress signaling, improving sleep quality, and helping alleviate depressive symptoms, particularly in patients with MDD accompanied by insomnia or persistent hyperarousal. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Major Depressive Disorder. • ALTO-300: Alto Neuroscience ALTO-300 is an investigational, orally administered small-molecule melatonergic agonist and serotonergic antagonist. Also known as agomelatine, the drug is approved for MDD in several countries outside the United States and is being developed by Alto using a precision psychiatry approach. Its mechanism of action (MOA) involves agonism of melatonin MT1 and MT2 receptors to restore circadian rhythms and antagonism of serotonin 5-HT2C receptors, which enhances dopamine and norepinephrine release in the frontal cortex. This dual mechanism is intended to improve depressive symptoms, sleep regulation, and emotional functioning in biomarker-selected patients with MDD. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Major Depressive Disorder. • ALTO-202: Alto Neuroscience ALTO-202 is an investigational, orally bioavailable small-molecule negative allosteric modulator of the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor which is designed to harness the rapid antidepressant effects associated with NMDA receptor modulation while avoiding the dissociative adverse effects seen with agents such as ketamine. Its mechanism of action (MOA) involves selectively inhibiting the GluN2B-containing NMDA receptor, thereby modulating glutamatergic neurotransmission, reducing excessive excitatory signaling, and promoting synaptic plasticity to improve depressive symptoms. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Major Depressive Disorder. • TN-001: Transneural Therapeutics TN-001 is an investigational non-hallucinogenic neuroplastogen, small-molecule drug is designed to promote rapid and sustained neuroplasticity while avoiding the hallucinogenic effects associated with classical psychedelics. Its mechanism of action (MOA) involves partial agonism of the serotonin 5-HT receptor and antagonism of the 5-HT_2B receptor, which stimulates synaptogenesis and enhances neural connectivity without inducing hallucinogenic activity. By restoring dysfunctional neural circuits implicated in depression, TN-001 aims to produce rapid and durable antidepressant effects. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Major Depressive Disorder. Further product details are provided in the report…….. Major Depressive Disorder: Therapeutic Assessment This segment of the report provides insights about the different Major Depressive Disorder drugs segregated based on following parameters that define the scope of the report, such as: • Major Players in Major Depressive Disorder There are approx. 75+ key companies which are developing the therapies Major Depressive Disorder. The companies which have their Major Depressive Disorder drug candidates in the most advanced stage, i.e. Phase III include, Helus Pharma and others. • Phases DelveInsight’s report covers around 75+ products under different phases of clinical development like • Late stage products (Phase III) • Mid-stage products (Phase II) • Early-stage product (Phase I) along with the details of • Pre-clinical and Discovery stage candidates • Discontinued & Inactive candidates • Route of Administration Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as • Intra-articular • Intraocular • Intrathecal • Intravenous • Ophthalmic • Oral • Parenteral • Subcutaneous • Topical • Transdermal • Molecule Type Products have been categorized under various Molecule types such as • Oligonucleotide • Peptide • Small molecule • Product Type Drugs have been categorized under various product types like Mono, Combination and Mono/Combination. Major Depressive Disorder: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Major Depressive Disorder therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Major Depressive Disorder drugs. Major Depressive Disorder Report Insights • Major Depressive Disorder Pipeline Analysis • Therapeutic Assessment • Unmet Needs • Impact of Drugs Major Depressive Disorder Report Assessment • Pipeline Product Profiles • Therapeutic Assessment • Pipeline Assessment • Inactive drugs assessment • Unmet Needs Key Questions Current Treatment Scenario and Emerging Therapies: • How many companies are developing Major Depressive Disorder drugs? • How many Major Depressive Disorder drugs are developed by each company? • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Major Depressive Disorder? • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Major Depressive Disorder therapeutics? • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? • What are the clinical studies going on for Major Depressive Disorder and their status? • What are the key designations that have been granted to the emerging drugs? Key Players • Helus Pharma • Janssen Research & Development • Alto Neuroscience • Transneural Therapeutics • Synphatec • ACADIA Pharmaceuticals • GH Research • SIMR Biotech • Supernus Pharmaceuticals, Inc. • Neurocrine Biosciences • Takeda • Xenon Pharmaceuticals Inc. • Eli lilly and Company • Abbvie Inc. • Autobahn Therapeutics Key Products • HLP003 • Seltorexant • ALTO-300 • TN-001 • SP-101 • ACP-211 • Mebufotenin • Major depressive disorder therapeutic • SPN-820 • Osavampator • Azetukalner • ALTO-202 • Brenipatide • Icalcaprant • Elunetirom